With the advent of biosimilars, retina specialists can expect changes to the clinical and payer landscape in the management of chronic retinal disease with anti-VEGF treatment. ASRS is monitoring the situation closely and has provided the following resources to assist members and the public understand the impact practices. Specifically, ASRS reiterates our across-the-board opposition to any step therapy protocols that mandate a retina specialist use a specific drug or sequence of drugs, whether they be FDA-approved originator products, biosimilars, or off-label repackaged drugs.

 If you need assistance or have questions, please contact Allison Madson, vice president of health policy, at or 312-578-8760.